Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its ...
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The ...
UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. A live question and answer session ...
ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations and ...
ProPhase Labs received a 180-day extension from Nasdaq to meet its $1.00 bid price compliance requirement. ProPhase Labs Inc. announced that it has received a 180-day extension from Nasdaq to meet the ...
The latest price target for ProPhase Labs (NASDAQ:PRPH) was reported by HC Wainwright & Co. on February 21, 2024. The analyst firm set a price target for $11.00 expecting PRPH to rise to within 12 ...
In a challenging market environment, ProPhase Labs, Inc. (PRPH) stock has touched a 52-week low, reaching a price level of $1.99. This latest dip underscores a difficult period for the company, which ...
ProPhase Labs (NASDAQ:PRPH) has received an extension of 180 calendar days from The Nasdaq to regain compliance with the Nasdaq's minimum $1.00 bid price requirement. NASDAQ stated that it based its ...
In a challenging market environment, ProPhase Labs, Inc. (PRPH) stock has touched a 52-week low, reaching a price level of $1.99. This latest dip underscores a difficult period for the company, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results